PDCD1 and melanoma: Pembrolizumab is a PD-1 immune checkpoint inhibitor that has significantly increased overall survival in a broad array of cancer types, including melanoma, non-small cell lung cancer, renal cell carcinoma, and microsatellite instability-high or mismatch repair-deficient cancer [14].